D'Alterio C, Zannetti A, Trotta AM, Ieranò C, Napolitano M, Rea G, Greco A, Maiolino P, Albanese S, Scognamiglio G, Tatangelo F, Tafuto S, Portella L, Santagata S, Nasti G, Ottaiano A, Pacelli R, Delrio P, Botti G, Scala S
New CXCR4 Antagonist Peptide R (Pep R) Improves Standard Therapy in Colorectal Cancer
Cancers (ISSN: 2072-6694linking), 2020 Jul 18; 12(7): 1952-1952.

Pelagalli A, Nardelli A, Lucarelli E, Zannetti A, Brunetti A
Autocrine signals increase Ovine Mesenchymal Stem Cells migration through Aquaporin-1 and CXCR4 overexpression
J Cell Physiol (ISSN: 1097-4652electronic, 0021-9541linking), 2018 Jan 18; 233(8): 6241-6249.

Brancaccio D, Diana D, Di Maro S, Di Leva FS, Tomassi S, Fattorusso R, Russo L, Scala S, Trotta AM, Portella L, Novellino E, Marinelli L, Carotenuto A
Ligand-Based NMR Study of C-X-C Chemokine Receptor Type 4 (CXCR4)-Ligand Interactions on Living Cancer Cells
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2018; 61(7): 2910-2923.

Santagata S, Portella L, Napolitano M, Greco A, D'Alterio C, Barone MV, Luciano A, Gramanzini M, Auletta L, Arra C, Zannetti A, Scala S
A novel CXCR4-targeted near-infrared (NIR) fluorescent probe (Peptide R-NIR750) specifically detects CXCR4 expressing tumors
Sci Rep (ISSN: 2045-2322, 2045-2322electronic, 2045-2322linking), 2017 May 31; 7(1): 2554-2554.

Fontanella R, Pelagalli A, Nardelli A, D'Alterio C, Ierano C, Cerchia L, Lucarelli E, Scala S, Zannetti A
A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell-mediated osteosarcoma and hepatocellular carcinoma cell migration and invasion
Cancer Lett (ISSN: 0304-3835), 2015 Oct 27; 370(1): 100-107.

Calce E, Vitale RM, Scaloni A, Amodeo P, De Luca S
Air oxidation method employed for the disulfide bond formation of natural and synthetic peptides
Amino Acids (ISSN: 0939-4451, 1438-2199, 1438-2199electronic), 2015; 47(8): 1507-1515.

Vincenzi M, Costantini S, Scala S, Tesauro D, Accardo A, Leone M, Colonna G, Guillon J, Portella L, Trotta AM, Ronga L, Rossi F
Conformational ensembles explored dynamically from disordered peptides targeting chemokine receptor CXCR4
Int J Mol Sc (ISSN: 1422-0067, 1661-6596, 1422-0067linking), 2015; 16(6): 12159-12173.

Neve Polimeno M, Ierano C, D'Alterio C, Simona Losito N, Napolitano M, Portella L, Scognamiglio G, Tatangelo F, Maria Trotta A, Curley S, Costantini S, Liuzzi R, Izzo F, Scala S
CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not
Cell Mol Immunol (ISSN: 1672-7681), 2014 Nov 3; 12(4): 474-482.

D'Alterio C, Avallone A, Tatangelo F, Delrio P, Pecori B, Cella L, Pelella A, D'Armiento FP, Carlomagno C, Bianco F, Silvestro L, Pacelli R, Napolitano M, Iaffaioli RV, Scala S
A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients
Int J Cancer (ISSN: 0020-7136), 2014 Jul 15; 135(2): 379-390.

Portella L, Vitale R, De Luca S, D'Alterio C, Ieranò C, Napolitano M, Riccio A, Polimeno MN, Monfregola L, Barbieri A, Luciano A, Ciarmiello A, Arra C, Castello G, Amodeo P, Scala S
Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases
Plosone (ISSN: 1932-6203, 1932-6203electronic), 2013 Sep 13; 8(9): N/D-N/D.

Lusso P, Vangelista L, Cimbro R, Secchi M, Sironi F, Longhi R, Faiella M, Maglio O, Pavone V
Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity
Faseb J (ISSN: 0892-6638, 0892-6638linking), 2011 Apr; 25(4): 1230-1243.

Napolitano M, Ottaiano A, Mauro F, Ieranò C, Satriano R, Pacelli R, Franco R, De Angelis V, Castello G, Scala S
CD4(+)CD45RA(+)CXCR4(+) lymphocytes are inversely associated with progression in stages I-III melanoma patients
Cancer Immunol Immunother (ISSN: 0340-7004, 0340-7004linking), 2010 Apr; 59(4): 511-517.

Scala S, Portella L, Napolitano M, Consales C, Polimeno MN, D'Alterio C,  Palma G, Arra C, Vitale R, Amodeo P,  De Luca S, Monfrecola L, Castello G
Design, synthesis, and functional characterization of new cyclepeptides inhibitors for C-X-C chemokine receptor-4 (CXCR4)
Meetingproceedings Of The American Association For Cancer Research Annual (ISSN: 0197-016x), 2010 Apr; 51: N/D-N/D.

Amodeo P, Castello G, De Luca S, Scala S, Siani A, Vitale RM
CYCLIC PEPTIDES BINDING CXCR4 RECEPTOR AND RELATIVE MEDICAL AND DIAGNOSTIC USES
Patent, 2010; PctWo2011092575: Pct-Pct.

Ierano C, Giuliano P, D'Alterio C, Cioffi M, Mettivier V, Portella L, Napolitano M, Barbieri A, Arra C, Liguori G, Franco R, Palmieri G, Rozzo C, Pacelli R, Castello G, Scala S
A point mutation (G574A) in the chemokine receptor CXCR4 detected in human cancer cells enhances migration
Cell Cycle (ISSN: 1538-4101), 2009 Apr 15; 8(8): 1228-1237.

Benedetti E, Morelli G, Della Moglie R,  De Luca S, Aloj L, Ciarmiello A, Lastoria S, Arra C, D'Alessio A, Tarallo L
Radiolabeled peptides as CXCR4 ligands
Understanding Biology Using Peptides, 2006; 80(4): N/D-N/D.

Palladino P, Tizzano B, Pedone C, Ragone R, Rossi F, Saviano G, Tancredi T, Benedetti E
Structural determinants of unexpected agonist activity in a retro-peptide analogue of the SDF-1α N-terminus
Febs Lett (ISSN: 0014-5793, 0014-5793print, 1873-3468electronic), 2005 Oct 10; 579(24): 5293-5298.

Palladino P, Pedone C, Ragone R, Rossi F, Saviano M, Benedetti E
A simplified model of the binding interaction between stromal cell-derived factor-1 chemokine and CXC chemokine receptor
Protein Pept Lett (ISSN: 0929-8665, 1875-5305), 2003 Apr; 10(2): 133-138.

Palladino P, De Capua A, Pedone C, Ragone R, Rossi F, Limatola C, Ragozzino D, Benedetti E
A simplified model of the interaction between SDF-1 chemokine and the CXCR4 receptor
Peptide Revolution, 2003 Apr; 10(2): 133-138.